Sarcopenia Treatment Market Intelligence Report Covers Trends, Segments And Regional Growth

The market for sarcopenia treatments is on the brink of significant expansion, driven by ongoing advancements in medical research and increasing awareness of muscle health among aging populations. As the demand for effective management of muscle loss continues to rise, the sector is set to witness promising developments fueled by innovative therapies and growing healthcare investments. Here is a detailed look at the current outlook, key players, market trends, and segmentation within the sarcopenia treatment industry.

Projected Growth and Market Size for Sarcopenia Treatments Through 2030
The sarcopenia treatment market is anticipated to experience substantial growth, reaching a valuation of $4.97 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 6.0%. The forecast period's growth is largely driven by breakthroughs in pharmacological therapies, heightened emphasis on early detection and treatment, increased expenditure on geriatric healthcare, the rise in chronic conditions impacting muscle function, and a surge in clinical trials focusing on muscle regeneration. Additionally, the market will benefit from the growing use of combined medication and exercise regimens, the adoption of nutritional supplements specifically targeting sarcopenia, expanding research into myostatin inhibitors and anabolic compounds, better diagnosis rates among elderly patients, and the integration of physical therapy into standard care practices.

The sarcopenia treatment market size has grown strongly in recent years. It will grow from $3.72 billion in 2025 to $3.94 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to growing elderly population base, increasing awareness of age-related muscle loss, reliance on physical therapy and nutritional support, limited availability of approved drug therapies, rising incidence of mobility-related disorders.

Download a free sample of the sarcopenia treatment market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13926&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Drivers Behind the Rise of the Sarcopenia Treatment Market
Pharmaceutical companies and research institutions are focusing more on developing advanced treatment options, which is a key factor propelling this market forward. Clinical studies, which rigorously assess the safety and efficacy of new therapies, play a critical role in introducing innovative solutions that meet patient needs more effectively.
For example, in September 2023, Biophytis, a biotech firm based in France, gained FDA approval to commence the SARA-31 Phase 3 clinical trial. This study will evaluate Sarconeos (BIO101) for its ability to treat sarcopenic individuals at risk of mobility impairments. The trial represents a significant step in enhancing therapeutic approaches and aims to deliver benefits in safety and efficacy for patients suffering from severe sarcopenia. Approximately 900 patients aged 65 and older, exhibiting low walking speed and reduced hand grip strength, will participate. The study's main goals include assessing major mobility disability risk, walking speed, grip strength, and quality of life as reported by patients.

Leading Firms Influencing the Sarcopenia Treatment Market
The sarcopenia treatment landscape is shaped by numerous key players, including Pfizer Inc, F Hoffmann La Roche, Merck Sharp And Dohme Corp, AbbVie Inc, Bayer AG, Novartis AG, Sanofi SA, Abbott Laboratories Inc, GlaxoSmithKline plc, Eli Lilly And Company, BASF SE, Nestle Health Science, Haleon Group Of Companies, DSM, Amway Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt Ltd, and Nutrafill.
A notable transaction took place in August 2023 when Eli Lilly and Company, a US pharmaceutical giant, acquired Versanis Bio for $1.925 billion. This deal added Versanis' leading candidate, bimagrumab, to Lilly's portfolio. Bimagrumab is currently in a Phase 2b trial evaluating its use both alone and together with semaglutide in adults with obesity or overweight conditions. Versanis Bio is a US-based biotech firm dedicated to developing sarcopenia therapies.

View the full sarcopenia treatment market report:
https://www.thebusinessresearchcompany.com/report/sarcopenia-treatment-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends Positively Impacting Sarcopenia Treatment Market Growth
Increasingly, companies are prioritizing the advancement of multiple clinical options to offer improved treatment choices for patients. Clinical studies remain crucial in validating the safety and effectiveness of these novel interventions.
For instance, the recent FDA-approved Phase 3 SARA-31 study by Biophytis highlights growing momentum in innovative pharmaceutical approaches. This trial not only addresses mobility disability but also focuses on patient-centric outcomes such as walking speed and grip strength, signaling a holistic approach to managing sarcopenia.

How the Sarcopenia Treatment Market Is Organized by Key Segments
The sarcopenia treatment market breaks down into several specific categories:
1) By Treatment Type:
- Protein Supplements
- Vitamin B12 Supplements
- Vitamin D and Calcium Supplements
- Other Treatment Types
2) By Sarcopenia Type:
- Primary Sarcopenia
- Secondary Sarcopenia
3) By Administration Route:
- Oral
- Parenteral
- Enteral
4) By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Channels
Further subcategories provide more detail within these groups, such as protein supplements segmented into whey protein, casein protein, soy protein, and plant-based protein. Vitamin B12 supplements are divided into cyanocobalamin and methylcobalamin, while vitamin D and calcium supplements include vitamin D2, vitamin D3, calcium carbonate, and calcium citrate. The "Other Treatment Types" category encompasses exercise programs, hormone replacement therapy, and additional nutritional interventions.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.